Payment overview · 2025
General Payments
$229.84
12 reported records · 10 companies
Healthcare provider profile · identity verified
Gregg M Hallbauer, DO
Allopathic & Osteopathic Physicians|Family Medicine · CONROE, TX · NPI 1922007343
Verified facts
What the public records show
CMS Open Payments records show Gregg M Hallbauer, DO received $229.84 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.72 | 22.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.14 | 11.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.58 | 10.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.39 | 10.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.35 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.84 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.30 | 7.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.29 | 7.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.81 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.42 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.84 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.76 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 248 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 71 |
| Lisinopril | Lisinopril | 164 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 62 |
| Losartan Potassium | Losartan Potassium | 143 | 62 |
| Metformin Hcl | Metformin Hcl | 129 | 52 |
| Gabapentin | Gabapentin | 128 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 55 |
| Morphine Sulfate Er | Morphine Sulfate | 102 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 45 |
| Sertraline Hcl | Sertraline Hcl | 86 | 37 |
| Simvastatin | Simvastatin | 77 | 35 |
| Montelukast Sodium | Montelukast Sodium | 72 | 32 |
| Furosemide | Furosemide | 71 | 36 |
| Omeprazole | Omeprazole | 71 | 35 |
| Glimepiride | Glimepiride | 70 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 28 |
| Ozempic | Semaglutide | 64 | 17 |
| Trazodone Hcl | Trazodone Hcl | 60 | 33 |
| Prednisone | Prednisone | 56 | 45 |
| Allopurinol | Allopurinol | 54 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 24 |
| Potassium Chloride | Potassium Chloride | 53 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 20 |
| Methadone Hcl | Methadone Hcl | 45 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 43 | suppressed |
| Eliquis | Apixaban | 41 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 15 |
| Pregabalin | Pregabalin | 36 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Clonazepam | Clonazepam | 34 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 19 |
| Meloxicam | Meloxicam | 31 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 14 |
| Bupropion Xl | Bupropion Hcl | 28 | 16 |
| Carvedilol | Carvedilol | 28 | 15 |
| Mirtazapine | Mirtazapine | 28 | 14 |
| Temazepam | Temazepam | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 15 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 12 |
| Tramadol Hcl | Tramadol Hcl | 25 | 16 |
| Buspirone Hcl | Buspirone Hcl | 24 | 14 |
| Myrbetriq | Mirabegron | 24 | 12 |
| Famotidine | Famotidine | 23 | 13 |
| Januvia | Sitagliptin Phosphate | 23 | 12 |
| Atenolol | Atenolol | 22 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 20 |
| Azithromycin | Azithromycin | 20 | 20 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valsartan | Valsartan | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | 12 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Glipizide | Glipizide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.84 · 12 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, FARXIGA, Fluad, Flucelvax, GEMTESA, OTEZLA, PREVNAR 20, REPATHA, SYMPLICITY G3, VOQUEZNA, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error